A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission
Zaid Abdel Rahman(King Hussein Cancer Center), Partow Kebriaei(Cellular Therapeutics (United Kingdom)), Nitin Jain(The University of Texas MD Anderson Cancer Center), Vinod Pullarkat(City of Hope), James M. Foran(Memorial Sloan Kettering Cancer Center), Tamer Othman(City Of Hope National Medical Center), Celina Ledesma(The University of Texas MD Anderson Cancer Center), Ibrahim Aldoss(City Of Hope National Medical Center), Razan Mohty(University of Alabama at Birmingham), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Yenny Alejandra Moreno Vanegas(WinnMed), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Hassan B. Alkhateeb(Mayo Clinic), Paul Koller(City of Hope), Patricia T. Greipp(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Ryotaro Nakamura(City of Hope), Stephen J. Forman(City of Hope), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Rima M. Saliba, Gabriela Rondón(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Mohamed A. Kharfan‐Dabaja(Mayo Clinic in Florida)
Cited by 6
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k